EP 14 | The Growth Hormone Hack: What Actually Works?
ICONOCAST — EP 14 | The Growth Hormone Hack: What Actually Works?
Channel: ICONOCAST · Our label: SELLER-CLINIC podcast (per census). Labeled, never neutral. · Source: youtube.com/watch?v=PAZAzBeTo4M
What this video covers
I’m Chris Potter, your host, and today we’re going to talk about growth hormone secretagogues. But before we do, I want to do a little housekeeping before we start today’s episode. I’ve gotten some feedback about the podcast and I’ve been told that it sounds a little too clinical or sometimes it feels like I am speaking to another healthcare professional. My patients at my clinic have also let me know that I have been too uptight and I’m not coming across as I do in my clinic, where I frequently use humor and plain speak.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- Some have FDA-level clinical trial data, while others have a good mechanistic rationale but limited human studies.
- It was actually FDA-approved at one point in the ’90s for growth hormone deficiency in children.
- Clinical studies have shown significant growth hormone increases, meaningful gains in lean body mass, and subjective improvements in sleep quality.
- It is the only growth hormone secretagogue currently FDA-approved, and it is sold under the brand name Egrifta.
- In phase 3 randomized controlled trials, which are the gold standard in clinical evidence, tesamorelin reduced deep visceral fat by 15 to 20% over a 26-week period.
- On the regulatory side, MK-677 is not FDA-approved, and under current 503A pharmacy rules, it cannot legally be compounded as a prescription product in the US.
Read next
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.